Head-To-Head Evidence Versus Oncotype Dx Further Demonstrates Superior Clinical Accuracy Of bioTheranostics’ Breast Cancer Index For ER+ Patients

CHICAGO--(BUSINESS WIRE)--bioTheranostics, Inc., today announced additional findings from the landmark TransATAC trial, the first head-to-head study between its Breast Cancer Index (BCI) and Oncotype Dx for estrogen receptor-positive (ER+) breast cancer patients. Patients previously classified into low-, intermediate-, or high-risk groups by Oncotype DX were successfully reclassified by the BCI with statistical and clinical significance for risk of recurrence between 0–10 years following diagnosis and initial treatment. The results were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting in Chicago.

Help employers find you! Check out all the jobs and post your resume.